Literature DB >> 23043415

(99m)Tc-MAG3-aptamer for imaging human tumors associated with high level of matrix metalloprotease-9.

Sonia Da Rocha Gomes1, Julie Miguel, Laurent Azéma, Sandrine Eimer, Colette Ries, Eric Dausse, Hugues Loiseau, Michèle Allard, Jean-Jacques Toulmé.   

Abstract

The human matrix metalloprotease 9 (hMMP-9) is involved in many physiological processes such as tissue remodeling. Its overexpression in tumors promotes the release of cancer cells thus contributing to tumor metastasis. It is a relevant marker of malignant tumors. We selected an RNA aptamer containing 2'-fluoro, pyrimidine ribonucleosides, that exhibits a strong affinity for hMMP-9 (K(d) = 20 nM) and that discriminates other human MMPs: no binding was detected to either hMMP-2 or -7. Investigating the binding properties of different MMP-9 aptamer variants by surface plasmon resonance allowed the determination of recognition elements. As a result, a truncated aptamer, 36 nucleotides long, was made fully resistant to nuclease following the substitution of every purine ribonucleoside residue by 2'-O-methyl analogues and was conjugated to S-acetylmercaptoacetyltriglycine for imaging purposes. The resulting modified aptamer retained the binding properties of the originally selected sequence. Following (99m)Tc labeling, this aptamer was used for ex vivo imaging slices of human brain tumors. We were able to specifically detect the presence of hMMP-9 in such tissues.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23043415     DOI: 10.1021/bc300146c

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  11 in total

1.  Cell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo.

Authors:  Xidong Wu; Huiyu Liang; Yan Tan; Chao Yuan; Shuji Li; Xiaowen Li; Guiping Li; Yusheng Shi; Xingmei Zhang
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

2.  Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas.

Authors:  David Kryza; Frédéric Debordeaux; Laurent Azéma; Aref Hassan; Olivier Paurelle; Jürgen Schulz; Catherine Savona-Baron; Elsa Charignon; Pauline Bonazza; Jacqueline Taleb; Philippe Fernandez; Marc Janier; Jean Jacques Toulmé
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

Review 3.  Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery.

Authors:  Pascal Röthlisberger; Cécile Gasse; Marcel Hollenstein
Journal:  Int J Mol Sci       Date:  2017-11-16       Impact factor: 5.923

Review 4.  Current Advances in Aptamers for Cancer Diagnosis and Therapy.

Authors:  Shin-Ichiro Hori; Alberto Herrera; John J Rossi; Jiehua Zhou
Journal:  Cancers (Basel)       Date:  2018-01-03       Impact factor: 6.639

Review 5.  Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging.

Authors:  Leila Hassanzadeh; Suxiang Chen; Rakesh N Veedu
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-15

6.  RNA inhibitors of nuclear proteins responsible for multiple organ dysfunction syndrome.

Authors:  Kevin T Urak; Giselle N Blanco; Shambhavi Shubham; Li-Hsien Lin; Justin P Dassie; William H Thiel; Yani Chen; Vijay Kumar Sonkar; Beilei Lei; Shubha Murthy; Wade R Gutierrez; Mary E Wilson; Jonathan A Stiber; Julia Klesney-Tait; Sanjana Dayal; Francis J Miller; Paloma H Giangrande
Journal:  Nat Commun       Date:  2019-01-10       Impact factor: 14.919

7.  A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein.

Authors:  Hui Li; Juan Liu; Xiaojuan Xiao; Shuming Sun; Hui Zhang; Yibin Zhang; Weihua Zhou; Bin Zhang; Mridul Roy; Hong Liu; Mao Ye; Zi Wang; Feng Liu-Smith; Jing Liu
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-15       Impact factor: 8.886

Review 8.  Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach.

Authors:  Chris Vi; Giovanni Mandarano; Sarah Shigdar
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

9.  Oligonucleotide aptamers: new tools for targeted cancer therapy.

Authors:  Hongguang Sun; Xun Zhu; Patrick Y Lu; Roberto R Rosato; Wen Tan; Youli Zu
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-05       Impact factor: 10.183

10.  RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applications.

Authors:  Hui Li; Taek Lee; Thomas Dziubla; Fengmei Pi; Sijin Guo; Jing Xu; Chan Li; Farzin Haque; Xing-Jie Liang; Peixuan Guo
Journal:  Nano Today       Date:  2015-10-01       Impact factor: 20.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.